Skip to main
ATAI
ATAI logo

ATAI Stock Forecast & Price Target

ATAI Analyst Ratings

Based on 17 analyst ratings
Strong Buy
Strong Buy 71%
Buy 24%
Hold 6%
Sell 0%
Strong Sell 0%

Bulls say

ATAI Life Sciences NV is positioned favorably in the biopharmaceutical market due to its promising pipeline of psychedelic-based therapies, notably VLS-01 and EMP-01, which target prevalent mental health conditions such as treatment-resistant depression and social anxiety disorder. Recent data from clinical trials indicate that BPL-003 has the potential to demonstrate durable effects in alcohol use disorder, with significant reductions in depression scores observed and a favorable tolerance profile among patients. The advancements in both the BPL-003 and other therapeutic candidates bolster the company's strategic potential and highlight its commitment to transforming outcomes in mental health treatment, suggesting a strong future for the stock.

Bears say

ATAI Life Sciences NV has encountered significant challenges in its clinical development timeline, leading to delays in key trials for its psychedelic-based therapies, which raises concerns about its pipeline progression. The company's high cash burn rate and reliance on continual fundraising initiatives may strain its financial stability, particularly in a competitive market with increasing pressure on biopharmaceutical investments. Additionally, the uncertainty surrounding regulatory approvals and market acceptance of innovative treatments further exacerbates the risk profile of its stock.

ATAI has been analyzed by 17 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 24% recommend Buy, 6% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Atai Life Sciences BV and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Atai Life Sciences BV (ATAI) Forecast

Analysts have given ATAI a Strong Buy based on their latest research and market trends.

According to 17 analysts, ATAI has a Strong Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.82, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.82, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Atai Life Sciences BV (ATAI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.